What is Positron?
Positron specializes in the development and provision of high-precision molecular imaging systems, with a particular focus on cardiac PET and PET-CT solutions. Their advanced technology, exemplified by systems like the NeuSight PET-CT, is engineered to significantly improve the accuracy of cardiac diagnostics, reduce patient scan times, and ultimately elevate the standard of care for cardiovascular conditions. The company is dedicated to driving the broader adoption of PET imaging within cardiology by delivering not only cutting-edge imaging hardware but also comprehensive clinical support and demonstrable value to healthcare providers.
How much funding has Positron raised?
Positron has raised a total of $305.1M across 3 funding rounds:
Seed
$23.5M
Series A
$51.6M
Series B
$230M
Seed (2025): $23.5M with participation from Valor Equity Partners, Atreides Management, and Flume Ventures
Series A (2025): $51.6M led by 1517 Fund I, Flume Ventures, DFJ Growth, Unless, Atreides Management, and Valor Equity Partners
Series B (2026): $230M supported by DFJ Growth, Unless, Valor Equity Partners, Flume Ventures, and Jump Trading
Key Investors in Positron
Valor Equity Partners
Valor Equity Partners is a Chicago-based firm established in 2001, specializing in investment activities and providing financial services to businesses. They are a repeat investor in Positron's funding rounds.
Atreides Management
Atreides Management, founded in 2019 and based in Boston, Massachusetts, focuses on long-term investments in technology and consumer businesses across both public and private markets. They have participated in multiple funding rounds for Positron.
Flume Ventures
Flume Ventures is a network of experienced operators and founders dedicated to partnering with entrepreneurs to scale innovative ideas, providing mentorship and community support. They are a consistent backer of Positron's growth.
What's next for Positron?
With the recent infusion of major strategic capital, Positron is poised for significant expansion and innovation. The company's trajectory, marked by consistent funding rounds from Seed to Series B, indicates a strong investor confidence in its technological advancements and market strategy. This latest investment is anticipated to fuel further research and development, enhance manufacturing capabilities, and broaden market penetration for its advanced cardiac imaging solutions. Positron's commitment to improving diagnostic accuracy and patient outcomes positions it for continued leadership in the evolving landscape of cardiovascular healthcare technology.
See full Positron company page
